Advertisement

Tumor Biology

, Volume 35, Issue 7, pp 6501–6509 | Cite as

Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients

  • Hatem A. El-mezayen
  • Hossam Darwish
Research Article

Abstract

Hepatocellular carcinoma (HCC) is often diagnosed at advanced stage where effective therapies are lacking. Identification of new scoring system is needed to discriminate HCC patients from those with chronic liver disease. Based on the link between vascular endothelial growth factor (VEGF) and HCC progression, we aimed to develop a novel score based on combination of VEGF and routine laboratory tests for early prediction of HCC. VEGF was assayed for HCC group (123), liver cirrhosis group (210), and control group (50) by enzyme-linked immunosorbent assay (ELISA). Data from all groups were retrospectively analyzed including α-fetoprotein (AFP), international normalized ratio (INR), albumin and platelet count, transaminases, and age. Areas under receiving operating curve (ROC) were used to develop the score. A novel index named hepatocellular carcinoma-vascular endothelial growth factor score (HCC-VEGF score) = 1.26 (numerical constant + 0.05 × AFP (U l−1) + 0.038 × VEGF (ng ml−1) + 0.004 × INR − 1.02 × albumin (g l−1) − 0.002 × platelet count × 109 l − 1 was developed. HCC-VEGF score produce area under ROC curve of 0.98 for discriminating HCC patients from liver cirrhosis with sensitivity of 91 % and specificity of 82 % at cutoff 4.4 (i.e., less than 4.4 considered cirrhosis and greater than 4.4 considered HCC). Hepatocellular carcinoma-VEGF score could replace AFP in HCC screening and follow up of cirrhotic patients.

Keywords

Hepatocellular carcinoma Cirrhosis HCV Diagnosis Tumor markers 

Notes

Acknowledgments

We thank Dr Mohamed El-Laban at Internal Medicine Department, Damietta General Hospital, Damietta, Egypt for providing us with the samples needed in this study.

Conflicts of interest

None.

References

  1. 1.
    Nafee AM, Pasha HF, Abd El Aal SM, Mostafa NA. Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential of viral-related hepatocellular carcinoma. Clin Biochem. 2012;45:1070–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Welzel TM, Graubard BI, Zeuzem S, El–Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463–71.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Gonzalez SA, Keeffe EB. Diagnosis of hepatocellular carcinoma: role of tumor markers and liver biopsy. Clin Liver Dis. 2011;15:297–306.CrossRefPubMedGoogle Scholar
  4. 4.
    Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Chen L, Ho DW, Lee NP, et al. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Ann Surg Oncol. 2010;17:2518–25.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Hao K, Luk JM, Lee NP, et al. Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer. 2009;9:389.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Kew MC. Hepatocellular carcinoma in developing countries: Prevention, diagnosis and treatment. World J Hepatol. 2012;4:99–104.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Mukozu T, Nagai H, Matsui D, Kanekawa T, Sumino Y. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. Anticancer Res. 2013;33:1013–1021.Google Scholar
  9. 9.
    Yoshiji H, Kuriyama S, Hicklin DJ, et al. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology. 1999;30:1179–86.CrossRefPubMedGoogle Scholar
  10. 10.
    Moon WS, Rhyu KH, Kang MJ, et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol. 2003;16:552–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Soresi M, Magliarisi C, Campagna P, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003;23:1747–53.PubMedGoogle Scholar
  12. 12.
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32.CrossRefPubMedGoogle Scholar
  13. 13.
    Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–26.CrossRefPubMedGoogle Scholar
  14. 14.
    Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat. 2004;11:383–93.CrossRefPubMedGoogle Scholar
  15. 15.
    Giannelli G, Fransvea E, Trerotoli P, et al. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta. 2007;383:147–52.CrossRefPubMedGoogle Scholar
  16. 16.
    Lehman EM, Wilson ML. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer. 2009;124:690–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502–10.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Camma C, Cabibbo G. Prognostic scores for hepatocellular carcinoma: none is the winner. Liver Int. 2009;29:478–80.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Harris SR, Schoeffner DJ, Yoshiji H, Thorgeirsson UP. Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Lett. 2002;179:95–101.CrossRefPubMedGoogle Scholar
  20. 20.
    El-Mezayen HA, el Toson SA, Darwish H, El-Badry E. Discriminant function based on parameters of hyaluronic acid metabolism and nitric oxide to differentiate metastatic from non-metastatic colorectal cancer patients. Tumour Biol. 2012;33:995–1004.CrossRefPubMedGoogle Scholar
  21. 21.
    Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Mise M, Arii S, Higashituji H, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology. 1996;23:455–64.CrossRefPubMedGoogle Scholar
  23. 23.
    Suzuki K, Hayashi N, Miyamoto Y, et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. 1996;56:3004–9.PubMedGoogle Scholar
  24. 24.
    Matsumata T, Kanematsu T, Takenaka K, Yoshida Y, Nishizaki T, Sugimachi K. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology. 1989;9:457–60.CrossRefPubMedGoogle Scholar
  25. 25.
    El-Zayadi AR, Badran HM, Barakat EM, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol. 2005;11:5193–8.PubMedCentralPubMedGoogle Scholar
  26. 26.
    Yeh SH, Chen PJ, Lai MY, Chen DS. Allelic loss on chromosomes 4q and 16q in hepatocellular carcinoma: association with elevated alpha-fetoprotein production. Gastroenterology. 1996;110:184–92.CrossRefPubMedGoogle Scholar
  27. 27.
    Kojiro M. Pathological evolution of early hepatocellular carcinoma. Oncology. 2002;62 Suppl 1:43–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Sherman M, Klein A. AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings. Hepatology. 2004;40:1465–73.CrossRefPubMedGoogle Scholar
  29. 29.
    Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology. 2004;127:S113–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Attallah AM, Omran MM, Attallah AA, et al. HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Br J Cancer. 2013;109:1657–65.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Fliser D, Zurbruggen I, Mutschler E, et al. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int. 1999;55:629–34.CrossRefPubMedGoogle Scholar
  32. 32.
    Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation. 2002;106:2919–24.CrossRefPubMedGoogle Scholar
  33. 33.
    Masuzaki R, Tateishi R, Yoshida H, et al. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. J Clin Gastroenterol. 2008;42:839–43.CrossRefPubMedGoogle Scholar
  34. 34.
    Attallah AM, El-Far M, Abdel Malak CA, et al. Evaluation of cytokeratin-1 in the diagnosis of hepatocellular carcinoma. Clin Chim Acta. 2011;412:2310–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Dai CY, Ho CK, Huang JF, et al. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J Hepatol. 2009;52:160–166.Google Scholar
  36. 36.
    Saad WE, Darwish WM, Davies MG, et al. Transjugular intrahepatic portosystemic shunts in liver transplant recipients: technical analysis and clinical outcome. AJR Am J Roentgenol. 2013;200:210–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Daskalow K, Rohwer N, Raskopf E, et al. Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma. J Mol Med (Berl). 2010;88:817–27.CrossRefGoogle Scholar
  38. 38.
    Tangkijvanich P, Tosukhowong P, Bunyongyod P, et al. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J Trop Med Public Health. 1999;30:110–4.PubMedGoogle Scholar
  39. 39.
    Bachtiar I, Santoso JM, Atmanegara B, et al. Combination of alpha-1-acid glycoprotein and alpha-fetoprotein as an improved diagnostic tool for hepatocellular carcinoma. Clin Chim Acta. 2009;399:97–101.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Chemistry DepartmentHelwan UniversityCairoEgypt
  2. 2.Medical Oncology DepartmentDamietta Cancer InstituteDamiettaEgypt

Personalised recommendations